Treatment Options for Symptomatic Uterine Fibroids

Diagnostic Assessment

• Pelvic ultrasound with Doppler is the first-line diagnostic method for uterine fibroids, with 90-99% sensitivity and 98% specificity 1
• MRI provides superior delineation of fibroid location, size, and number compared to ultrasound, and can differentiate fibroids from adenomyosis and endometriosis 1
• Saline infusion sonohysterography (SIS) improves visualization between endometrial pathologies and submucosal fibroids, showing good agreement with diagnostic hysteroscopy 2

Treatment Options

Surgical Approaches

• The American College of Radiology recommends hysterectomy as the only curative procedure when fertility preservation is not desired and symptoms are severe enough to warrant definitive treatment 2, 1
• Myomectomy is appropriate for women desiring fertility preservation, can be performed via hysteroscopy, laparoscopy, or laparotomy depending on fibroid location and size 1
• Important risks of myomectomy include significant intraoperative blood loss and development of postoperative adhesions that may affect future fertility 1

Minimally Invasive Interventions

• Uterine Artery Embolization (UAE) is an effective alternative to surgery with equivalent symptomatic improvement to myomectomy at 2 years 2, 1
• MR-guided Focused Ultrasound Surgery (MRgFUS) is an option for selected cases, using high-intensity ultrasound to ablate fibroid tissue 1

Medical Management

• Ulipristal Acetate (UPA) can reduce fibroid volume by approximately 30% after a single course and up to 70% after 4 courses, with Level I, A evidence supporting its use for symptomatic relief 3, 4
• The American College of Obstetricians and Gynecologists recommends UPA as a treatment option for symptomatic uterine fibroids, with a 30% volume reduction potentially yielding a diameter of 8.9 cm, which may still be symptomatic 3

Treatment Algorithm

• For a 10x8x9 cm symptomatic fibroid, if fertility is not desired and symptoms are severe, hysterectomy offers definitive treatment 1
• If fertility preservation is important, myomectomy (likely via laparotomy or advanced laparoscopy due to size) is recommended, with consideration of preoperative UPA to reduce fibroid size and minimize surgical blood loss 1, 3
• If surgery is contraindicated or the patient prefers non-surgical options, UAE is a validated alternative with good long-term outcomes 1

Important Considerations

• For a fibroid of this size (10x8x9 cm), medical therapy alone is unlikely to provide sufficient volume reduction for complete symptom resolution 3, 4
• The American College of Obstetricians and Gynecologists recommends that treatment be guided by the patient's predominant symptoms (bleeding vs. bulk-related) and reproductive goals 3

Imaging and Surgical Management of Fibroid Degeneration

Diagnostic Imaging Recommendations

• In women presenting with acute pelvic pain and known fibroids, urgent imaging should be performed to exclude other acute pathologies—including twisted adnexa, ruptured ectopic pregnancy, hemorrhagic ovarian cyst, ovarian malignancy, and uterine sarcoma, especially when rapid fibroid growth occurs in post‑menopausal patients. 5

Fertility‑Preserving Surgical Strategies

• For women desiring future fertility, a myomectomy performed after pregnancy is recommended when fibroids are symptomatic and larger than 3 cm. 5
• Hysteroscopic myomectomy is indicated for submucosal fibroids that cause abnormal uterine bleeding or infertility. 5
• Laparoscopic or open myomectomy should be considered for intramural or subserosal fibroids, with the surgical approach selected according to the fibroid’s size and anatomical location. 5

Management of Broad Ligament Fibroids in Women Seeking Fertility Preservation

Diagnostic Imaging

• Magnetic resonance imaging (MRI) is the preferred modality for precisely defining the size, exact location, and relationship of broad‑ligament fibroids to adjacent ureters, iliac vessels, and bladder, which is essential for safe surgical planning. 6

Surgical Management

• Surgical myomectomy (laparoscopic or open) is the definitive, fertility‑preserving treatment for symptomatic women with broad‑ligament fibroids; the choice between minimally invasive or open approach is guided by fibroid dimensions and anatomical complexity. 6
• Meticulous pre‑operative imaging and intra‑operative technique are required to identify and protect the ureters and pelvic vasculature, minimizing the risk of iatrogenic injury during fibroid excision. 6

Non‑Surgical Options (Not Recommended)

• Uterine artery embolization (UAE) is contraindicated for broad‑ligament fibroids because these lesions often receive blood supply from ovarian or other pelvic arteries, making embolization technically difficult and less effective. 7
• Hysteroscopic myomectomy is unsuitable for broad‑ligament fibroids, as the lesions are extra‑uterine and cannot be accessed via the transcervical route. 6

Management of Uterine Fibroids According to FIGO Classification – Evidence‑Based Recommendations

1. General Recommendations (All FIGO Types)

2. Submucosal Fibroids (FIGO Types 0‑2)

FIGO Type 0 – Pedunculated Submucosal

Medical Adjuncts for Types 0‑2

FIGO Type 2 – Submucosal ≥ 50 % Intramural

3. Intramural & Subserosal Fibroids (FIGO Types 3‑7)

FIGO Type 3 – 100 % Intramural, contacts endometrium

FIGO Type 4 – Pure Intramural

4. Medical Hormonal Therapies (Applicable to All FIGO Types)

5. Uterine Artery Embolization (UAE)

6. Fertility‑Focused Decision Pathway

Intramural Fibroids: Epidemiology, Clinical Impact, and Management

Epidemiology and Demographic Disparities

• Approximately 70 % of White women and over 80 % of Black women will have uterine fibroids by age 50, with intramural fibroids representing one of the most common subtypes【9】.
• Black women tend to develop symptomatic intramural fibroids at a younger age, undergo surgical treatment more frequently, and have lower utilization of minimally invasive options compared with White women, highlighting a need for equitable access to all therapies【9】.

Pathology

• Intramural fibroids are benign smooth‑muscle tumors composed of smooth‑muscle cells and connective tissue that arise within the myometrium and do not markedly protrude into the uterine cavity or serosal surface【9】.

Clinical Presentation

• Heavy or prolonged menstrual bleeding is common and can lead to anemia and fatigue【9】.
• Pelvic pressure or a sensation of fullness is frequently reported【9】.
• Urinary frequency or urgency may occur due to mass effect on the bladder【9】.
• Constipation is another bulk‑related symptom associated with intramural fibroids【9】.
• Dysmenorrhea (painful periods) is often present【9】.
• A substantial proportion of intramural fibroids remain asymptomatic and are discovered incidentally during imaging or surgery【10】.

Fertility Implications

• In assisted reproductive technology cycles, women with intramural fibroids have lower pregnancy rates (16.4 % vs 30.1 % in women without fibroids) and lower implantation rates (6.4 % vs 15.7 %) even when the uterine cavity is not distorted【10】.
• By contrast, subserosal fibroids do not significantly affect fertility (pregnancy rate ≈ 34.1 %), whereas submucosal fibroids have the greatest adverse impact (pregnancy rate ≈ 10 %)【10】.

Pregnancy‑Related Risks

• Pregnant patients with an existing intramural fibroid face higher risks of spontaneous abortion, preterm delivery, abnormal fetal presentation, and postpartum hemorrhage compared with pregnancies without fibroids【10】.